Clinical trials: Pulmonary Fibrosis, Idiopathic
Asthma, Chronic Obstructive Pulmonary Disease
A Study of Patients With Chronic Disease
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF
- Trial name
- NCT04263727
- Where
- 5 sites in United States
- Volunteers
- 579 people
- Sponsor
- Target PharmaSolutions, Inc.
Pulmonary Fibrosis, COPD
Multiple Breath Washout as a Method for Diagnosing Lung Diseases
Comparison of the new multiple-breath washout method (ndd Medizintechnik Zürich, Trueflow™/Truecheck™) with established methods of lung function diagnostics in patients with idiopathic pulmonary fibrosis, chronic obstructive…
- Conditions
- Pulmonary Fibrosis, COPD, Asthma
- Trial name
- NCT06179342
- Testing
- Multiple-Breath-Washout
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Wissenschaftliches Institut Bethanien e.V
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy
Post-marketing surveillance of Pirfenidone
- Trial name
- NCT03761082
- Testing
- NA(observation study)
- Volunteers
- 258 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Idiopathic Pulmonary Fibrosis
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis
This is an interventional double-blind randomized controlled trial, to investigate the short and long-term effects of a supervised exercise training program in patients with IPF, depending on alternate patterns of oxygen…
- Trial name
- NCT03326089
- Testing
- Pulmonary rehabilitation
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Corfu General Hospital
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Idiopathic Pulmonary Fibrosis
Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the…
- Trial name
- NCT03171870
- Testing
- high resolution computed tomography
- Volunteers
- 1 people
- Sponsor
- Assiut University
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Usual Interstitial Pneumonia, Nonspecific Interstitial Pneumonia
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias
The diagnosis of idiopathic interstitial pneumonia (IIP) is based on computed tomography (CT) imaging, whereas lung function studies are used for staging and follow up.
- Trial name
- Dm&Vc (NCT02596841)
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis (IPF)
Short-term Effects of Supplemental Oxygen in Patients With IPF
Although exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary fibrosis (IPF) short-term effects of supplemental oxygen during walking have not been investigated yet.
- Trial name
- IPFO2 (NCT03050255)
- Testing
- Medical air, Oxygen (2Liter/min), Oxygen (4Liter/min)
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- Schön Klinik Berchtesgadener Land
IPF, Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Job Exposures Study
A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic…
- Trial name
- IPFJES (NCT03211507)
- Testing
- Computer-assisted telephone interview, Genetic analysis
- Where
- United Kingdom
- Volunteers
- 960 people
- Sponsor
- Imperial College London
Idiopathic Pulmonary Fibrosis
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Pirfenidone as anti-fibrosis drug developed in recent years demonstrated the potential anti- fibrotic effect, but so far there were no domestic studies about pirfenidone's efficacy and safety evaluation in china.
- Trial name
- IPF (NCT02136992)
- Testing
- Pirfenidone
- Volunteers
- 160 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Idiopathic Pulmonary Fibrosis
Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
Two oral medications, nintedanib and pirfenidone, were approved simultaneously by the FDA in October 2014 for the treatment of this disease.
- Trial name
- IPF-LTOS (NCT04316780)
- Testing
- Retrospective observational study- no intervention to occur.
- Where
- 8 sites in United States
- Volunteers
- 320 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Idiopathic Pulmonary Fibrosis
Nutritional Assessment in Idiopathic Pulmonary Fibrosis
In recent years nutritional status assumed increasing importance in the evaluation of chronic respiratory diseases, considering that their clinical course is often characterized by a progressive loss of weight and reduction of…
- Trial name
- NUTRIPF (NCT03770845)
- Where
- 9 sites in Italy
- Volunteers
- 100 people
- Sponsor
- San Gerardo Hospital
Idiopathic Interstitial Pneumonia
Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up
Interstitial lung diseases (ILD) represent a frequent complication of connective tissue diseases (CTDs), especially systemic sclerosis, idiopathic inflammatory myopathies and rheumatoid arthritis.
- Trial name
- EVOLIPAF (NCT04179058)
- Testing
- Follow-up
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Idiopathic Pulmonary Fibrosis
Real-life-persistence to Antifibrotic Treatments
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence…
- Trial name
- REPEAT (NCT06485635)
- Testing
- Nintedanib, Pirfenidone
- Where
- France
- Volunteers
- 10,646 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT04318704
- Testing
- Ifenprodil
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Algernon Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.
- Trial name
- NCT00212511
- Where
- United States
- Sponsor
- NYU Langone Health
Lung Diseases, Herpesvirus Infections
Herpesvirus in Idiopathic Pulmonary Fibrosis
The purpose of this study is to: 1) to develop a method to quantify Epstein Barr Virus (EBV) load in lung tissue of humans and to determine whether EBV viral load is significantly higher in lung tissue from patients with…
- Trial name
- NCT00228670
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Emory University
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar